Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant ...
www.nejm.org › full › NEJMoa2309169
Dec 6, 2023 · Mirvetuximab soravtansine-gynx (MIRV) is a first-in-class antibody–drug conjugate targeting folate receptor α (FRα), a biomarker that is ...
Dec 6, 2023 · Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody–drug conjugate targeting folate receptor α (FRα), is approved for the ...
Dec 7, 2023 · FORWARD I (GOG 3011): a phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody- drug conjugate, versus ...
Dec 6, 2023 · Mirvetuximab soravtansine-gynx is a first-in-class drug recently approved for this condition. New research findings are summarized in a short ...
People also ask
Is mirvetuximab soravtansine better than chemotherapy in FRα expressing recurrent ovarian cancer?
Is mirvetuximab approved by the FDA?
What is the brand name for mirvetuximab soravtansine?
Is mirvetuximab chemo?
May 1, 2023 · Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor α (FRα). SORAYA is a single-arm, phase II study ...
Dec 11, 2023 · NEJM Journal Watch · Is Mirvetuximab Soravtansine Better Than Chemotherapy in FRα-Expressing Recurrent Ovarian Cancer?
In patients with platinum-resistant EOC, MIRV did not result in a significant improvement in PFS compared with chemotherapy.
Mar 1, 2021 · Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and ...
Purpose. Single-agent chemotherapies have limited activity and considerable toxicity in patients with platinum-resistant epithelial ovarian cancer (PROC).
Apr 24, 2024 · Elahere is approved to treat people with advanced, platinum-resistant ovarian cancer whose tumors overproduce a protein called FR-α.
Missing: nejm | Show results with:nejm